Bio

Bio


Caroline Fisher, MD, is a Clinical Associate Professor of Ophthalmology at Stanford University Hospital and Clinics. She specializes in cataract and glaucoma surgery, including minimally invasive glaucoma surgery.

She completed her undergraduate education at Stanford University, obtaining both a Bachelor of Science degree in Biology and a Bachelor of Arts degree in Spanish, with Departmental Honors. She earned her medical degree from Stanford University School of Medicine and then went on to her internship at the University of Pennsylvania Presbyterian Hospital. She completed her ophthalmology residency at NYU/ Manhattan Eye, Ear, Throat Hospital. She then returned to Stanford for her Glaucoma Fellowship.

Dr. Fisher is Director of the Stanford Belize Vision Clinic, dedicated to promoting eye health and care in Belize, and providing an international rotation for Stanford Ophthalmology Residents. She is also an Office of Faculty Development and Diversity Liaison and is currently one of the Stanford Network for Advancement and Promotion (SNAP) Cohort Leaders.

Clinical Focus


  • Ophthalmology
  • Glaucoma
  • Cataract

Academic Appointments


Administrative Appointments


  • Associate Clinic Chief, Byers Eye Institute Department of Ophthalmology (2018 - Present)
  • Director, Stanford Belize Vision Clinic (2017 - Present)
  • Liaison, Office of Faculty Development and Diversity (2014 - Present)

Honors & Awards


  • Plager Faculty Teaching Award Department of Ophthalmology, Stanford Ophthalmology (2017)
  • Alpha Omega Alpha Medical Honor Society, Alpha Omega Alpha, AOA (2015)
  • Gerbode Medical Scholar, Stanford University School of Medicine (1998-1999)
  • Excellence in Teaching Award, Department of Biology Stanford University (1998)
  • Excellence in Teaching Award, Department of Biology Stanford University (1997)
  • Excellence in Teaching Award, Department of Biology Stanford University (1996)
  • Major Golden Grant for Humanities Scholarship and Creative Arts, Stanford University (1996)
  • Sigma Delta Pi National Literary Honor Society, Sigma Delta Pi, Stanford University (1996)

Boards, Advisory Committees, Professional Organizations


  • Member, American Academy of Ophthalmology (2003 - Present)
  • Member, Clinical Educator Task Force Committee (2015 - Present)
  • Member, American Glaucoma Society (2014 - Present)

Professional Education


  • Medical Education: Stanford University School of Medicine Registrar (2002) CA
  • Internship: Presbyterian Medical Center of Philadelphia (2003) PA
  • Residency: New York University School of Medicine (2006) NY
  • Fellowship, Stanford University Hospital and Clinics, Glaucoma (2007)
  • Board Certification: Ophthalmology, American Board of Ophthalmology (2009)
  • BS, Stanford University, Biology (1997)
  • BA, Stanford University, Spanish (1997)

Research & Scholarship

Clinical Trials


  • Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension Not Recruiting

    This study will evaluate the efficacy and safety of bimatoprost SR in participants with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.

    Stanford is currently not accepting patients for this trial.

    View full details

  • Safety and Efficacy of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension Not Recruiting

    This study will evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.

    Stanford is currently not accepting patients for this trial. For more information, please contact Mariana Nunez, 650-724-3734.

    View full details

Publications

All Publications


  • Comparison of Using One Trabecular Microbypass Stent versus Two during Cataract Surgery at Two Sites: One-Year Follow-Up. BioMed research international Yang, S., Ittarat, M., Tran, E., Ferrell, P., Wang, G., Fisher, A. C., Li, Z., Chang, R. T. 2020; 2020: 1920352

    Abstract

    Purpose: To compare IOP and ocular hypotensive medication reduction of using one trabecular microbypass stent versus two in patients with open-angle glaucoma. Setting. Palo Alto Veterans Affairs (VA) Hospital and the Byers Eye Institute at Stanford University, Palo Alto, California, USA.Design: Retrospective case series.Methods: A chart review included patients who underwent trabecular microbypass implantation with cataract surgery in 2015-2017, with at least one-year follow-up. Subjects were divided into two groups by location (always one stent at Stanford versus two stents at the VA). Primary outcome measures included IOP and medication reduction at baseline and 12-month follow-up.Results: 132 subjects (166 eyes) were included. The preoperative IOP was 16.3 3.4mmHg on 2.6 1.1 medications in the one-stent group (N = 85) and 17.5 3.1mmHg on 2.7 0.6 medications in the two-stent group (N = 81). There was no significant difference between the two groups (p = 0.06). At the 12-month visit, there was a 13.37% 2.93 reduction in IOP in the 1-stent group (p ? 0.001) and 13.49% 2.69 in the 2-stent group (p ? 0.001); both were not significantly different from each other (p = 0.074). At 12 months, there was also a 14.5% reduction in medication use for the 1-stent group and 15.3% reduction in the 2-stent group, both statistically significant from baseline, (p = 0.022 and p = 0.037, respectively).Conclusions: Implantation with either one or two stents during cataract surgery in patients with glaucoma demonstrated similar IOP and med reduction in both groups between the two sites.

    View details for DOI 10.1155/2020/1920352

    View details for PubMedID 32337227

  • Comparison of 1-Year Effectiveness of Trabecular Microbypass Stent implantation (iStent) in Conjunction With Phacoemulsification Among Mild, Moderate, and Severe Primary Open-angle Glaucoma Patients. Journal of glaucoma Chansangpetch, S., Ittarat, M., Yang, S., Fisher, A. C., Singh, K., Lin, S. C., Chang, R. T. 2020

    Abstract

    The study compared 1-year effectiveness of single trabecular microbypass stent (iStent) implantation with phacoemulsification among glaucoma severities in primary open-angle glaucoma. The study found that mild glaucoma had greater success rate and lower number of medications compared with moderate and severe glaucoma.To evaluate the effectiveness of iStent implantation in combination with cataract surgery in moderate to severe glaucoma compared with mild glaucoma.Medical charts of primary open-angle glaucoma subjects undergoing 1 iStent implantation were retrospectively reviewed. Glaucoma was classified on the basis of mean deviation (MD) of the preoperative standard automated perimetry into mild (MD>-6?dB), moderate (MD -6 to -12?dB), and severe (MD<-12?dB). Mixed effect regression models were performed to determine the effect of iStent at 1 year. The outcomes included as follows: (1) intraocular pressure (IOP) and the number of medications, (2) eyes with IOP ? severity-based target (18?mm?Hg for mild, 15?mm?Hg for moderate, 12?mm?Hg for severe) (2A) without medication, and (2B) with medication reduction.In total, 104 eyes from 89 subjects were analyzed. Cataract combined with iStent surgery significantly lowered the number of medications in all groups and significantly decreased IOP in moderate and severe glaucoma (P<0.05). There was significantly higher number of medications in moderate (?: 0.58, P=0.002) and severe (?: 1.20, P<0.001) compared with mild glaucoma. Eyes with moderate glaucoma had significantly lower rate of success (criterion 2A) compared with mild glaucoma [odds ratio (OR): 0.008, P=0.047]. Eyes with moderate and severe glaucoma had significantly lower rates of success (criterion 2B) (moderate vs. mild OR: 0.002, P=0.028; severe vs. mild OR: 0.026, P=0.026).Combined phacoemulsification with iStent seems to have a better IOP-lowering and medication-lowering effect in mild glaucoma cases versus those with moderate and severe glaucoma. This difference was found in real-world data over one-year follow-up period. Long-term studies with defined IOP goals and medication removal protocols are warranted.

    View details for DOI 10.1097/IJG.0000000000001542

    View details for PubMedID 32433095

  • Comparison of 1 year effectiveness of trabecular microbypass stent implantation (iStent) among mild, moderate, and severe primary open angle glaucoma Chansangpetch, S., Ittarat, M., Yang, S., Fisher, A. C., Singh, K., Lin, S. C., Chang, R. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2019
  • Recombinant human nerve growth factor (rhNGF) eye drops for glaucoma: Results from a prospective double - masked randomized controlled trial Nunez, M., Popova, L., Nguyen, B. T., Groth, S. L., Dennis, A., Li, Z., Khavari, T., Wang, S. Y., Chang, R., Fisher, A. C., Goldberg, J. L. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2019
  • Impact of Race on Press Ganey Measures of Ophthalmology Clinic Visits Chen, T., Chen, S., Lee, M., Fisher, A., Lin, C. C., Singh, K., Chang, R. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2018
  • Recombinant human nerve growth factor (rhNGF) eye drops for glaucoma: Interim results Popova, L., Nunez, M., Bac Tien Nguyen, Groth, S., Dennis, A., Li, Z., Khavari, T., Wang, S., Chang, R., Fisher, A., Goldberg, J. L. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2018
  • Characteristics of cataract surgery patients influencing Press Ganey patient satisfaction scores Lee, M., Chen, S., Chen, T., Fisher, A., Lin, C. C., Singh, K., Chang, R. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2018
  • Chapter 109: Automated Perimetry Diagnostic Modalities in Ophthalmology Duane's Ophthalmology Fisher, A., Prince A
  • Chapter 107: Modulation of Wound Healing Techniques Glaucoma, 1st Edition Fisher, A., Doshi A, Singh K 2009
  • Crystalline Retinopathy associated with retinal dialysis and chronic retinal detachment Retina Ciardella AP, Yannuzzi LA, Borodoker N, Mendoza C 2002; 22 (3): 360-2

Footer Links:

Stanford Medicine Resources: